We begin by examining the nuanced role of venture capital in mitigating risks associated with longevity biotech investments. The dialogue with Kelsey Moody, CEO of Ichor Life Sciences, offers a window into the sophisticated approaches being adopted to validate scientific breakthroughs before financial commitments are made, highlighting the intersection of scientific rigor and investment acumen.
— Read on longr.io/newsletter/vcs-should-derisk-longevity-investments/